The erythropoietic effect of recombinant human erythropoietin, epoetin alpha (rHuEPO), in promoting the growth of erythroid burst-forming units (BFU-E) was compared with darbepoetin alpha (DARB), a rHuEPO analogue obtained by site-directed mutagenesis. Human bone marrow cells derived from healthy donors were cultured with different concentrations of rHuEPO or DARB for 12 -21 days and BFU-E were counted using an inverted microscope. The EC 50 of rHuEPO was about 10-fold lower than DARB and the size of the colonies was significantly larger in rHuEPO-containing cultures using comparable concentrations. The maximum number of colonies obtained in some rHuEPO-containing cultures was also higher than for DARB. The number of colonies in DARB-containing cultures was increased, in part, by the addition of low concentrations of rHuEPO, but not by DARB, even at high concentrations. We conclude that DARB is not as effective as rHuEPO in supporting the in vitro growth of human BFU-E.
Introduction
Erythropoietin is a naturally occurring sialoglycoprotein hormone that is synthesized predominantly in the kidneys in response to tissue hypoxia. 1 Erythropoietin is essential for erythropoiesis and it is the primary regulator of this process. Erythropoietin binds to specific receptors on bone marrow progenitor cells, promoting their maturation into reticulocytes, which then mature into red blood cells in the blood circulation. While the mechanism that is mediated by erythropoietin has not been fully elucidated, recent data suggest that erythropoietin prevents apoptosis of the progenitor cells, allowing them to mature into red blood cells. 2 The gene for erythropoietin has been cloned and expressed in Chinese hamster ovary cells. 3, 4 Secreted recombinant human erythropoietin (epoetin alpha, rHuEPO) is structurally very similar, if not identical, to endogenous human erythropoietin. 4, 5 Darbepoetin alpha (DARB), an analogue of rHuEPO, has been produced by site-directed mutagenesis to enrich glycosylation with the aim of prolonging serum half-life. 6, 7 DARB has been approved for use in the treatment of anaemia in chronic renal patients and for the treatment of chemotherapy-induced anaemia in cancer patients. The addition of two glycosylated moieties by site-directed mutagenesis has resulted in a molecule that is more negatively charged and has a higher molecular weight. Binding of DARB to the erythropoietin receptor (EPOR) is approximately five-fold less than rHuEPO due to steric hindrance created by the additional glycosylation. 8 To date, it is not known if there are any biological consequences at a cellular level of a reduced binding-constant for DARB as compared with that of rHuEPO.
Erythroid differentiation passes through sequential developmental stages. The pluripotent stem cell differentiates into early erythroid-committed progenitors called erythroid burst-forming units (BFU-E), which subsequently undergo differentiation into more mature progenitors, the erythroid colony-forming units (CFU-E). 9 These progenitors can be detected in vitro by virtue of their capacity to form clones of haemoglobin-synthesizing cells in cultures containing erythropoietin. While other growth factors such as interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) or stem cell factor are known to play a role in erythroid differentiation, erythropoietin has been established as the essential growth factor for differentiation and growth of erythroid bursts and colonies. 10 Erythropoietin responsiveness of cultured progenitors from bone marrow or peripheral blood of patients has been used successfully to evaluate and monitor different haematological diseases involving early or late progenitors. 11 This study was designed to compare the in vitro biological activity of rHuEPO and DARB by measuring their ability to support erythroid burst formation.
Materials and methods

BONE MARROW SAMPLES
Normal bone marrow samples were obtained from consenting healthy allogenic marrow donors admitted to the Princess Margaret Hospital for allogenic bone marrow transplantation.
LABORATORY CULTURES
Bone marrow samples were aspirated into sodium-heparinized syringes. The specimens were centrifuged with 60% Percoll™ to obtain a mononuclear cell suspension of density < 1.077 gm/ml. These cells were then suspended in tissue culture medium containing Iscove's Modified Dulbecco's MEM (IDMEM, Gibco, Grand Island, NY, USA), 5 × 10 5 M 2-mercaptoethanol, 30% fresh normal heparinized human plasma, 20% of a medium conditioned by peripheral leucocytes (PHA-LCM) 12 from a patient with haemochromatosis in the presence of phytohaemaglutinin (PHA-HA 15, Wellcome, Beckenham, UK), and methylcellulose at a final concentration of 0.9%. Different concentrations (IU) of rHuEPO or DARB, where 200 IU rHuEPO is equivalent to 1 µg of DARB, 7 were added to separate culture tubes containing cell suspension. rHuEPO was obtained from Ortho Biotech, Toronto, Ontario, Canada, and DARB was obtained from Amgen Canada. Aliquots (1 ml) of the cell suspension were plated into 35 mm Petri dishes (Lux, Rochester, NY, USA) and incubated for 12 -21 days at 37 o C in a humidified atmosphere supplemented with 5% CO 2 . The plates were examined by inverted microscopy and BFU-E-derived colonies were scored as small (> 50 -100 cells), medium (> 100 -500 cells), or large (> 500 -10 000+ cells).
MATHEMATICAL ESTIMATION OF EC 50 AND E max
The number of BFU-E-derived colonies was used to evaluate the efficacy and potency of both rHuEPO and DARB. The E max model was applied to quantify the number (#) of BFU-E-derived colonies versus rHuEPO concentrations: 9 #BFU-E colonies = E max C rHuEPO (1) EC 50 + C rHuEPO where E max was the maximum number of BFU-E-derived colonies and EC 50 denoted rHuEPO concentration eliciting 50% of the E max . Assuming that the number of BFU-E colonies is proportional to the concentration of rHuEPO bound to its receptor, the classical receptor occupancy theory implies that:
where k DrHuEPO denotes the equilibrium dissociation constant. 13 The same model was applied to describe the effect of DARB on the number of BFU-E-derived colonies. The parameters E max and EC 50 were estimated for each individual data point. The fittings were performed using the ordinary least squares estimator in ADAPT II. 14
ADDITIVE STUDIES
Human bone marrow cells from two subjects were cultured for 10 -14 days as described in the presence of different concentrations of both rHuEPO and DARB. rHuEPO and DARB molecules were assumed to compete for the same erythropoietin receptor expressed on BFU-E. The pharmacodynamic effect was calculated according to the number of BFU-E-derived colonies in a Petri dish after incubation at various rHuEPO (C rHuEPO ) and DARB (C DARB ) concentrations. The Ariens' effect model for competitive drug interaction 15 was applied to describe the number of BFU-E-derived colonies as equation (3) -see foot of page -where E maxrHuEPO = maximum effect if rHuEPO was administered alone; EC 50rHuEPO = rHuEPO concentration eliciting 50% of the maximum effect when administered alone; E maxDARB = maximum effect if DARB was administered alone; and EC 50DARB = DARB concentration eliciting 50% of the maximum effect when administered alone. According to the Ariens' competitive receptor binding theory: 15 EC 50rHuEPO = k DrHuEPO and EC 50DARB = k DDARB (4) where k DrHuEPO and k DDARB are equilibrium dissociation constants for rHuEPO and DARB, respectively. All data for any given subject were fitted simultaneously with equation (3) yielding estimates of four parameters: E maxrHuEPO , EC 50rHuEPO , E maxDARB and EC 50DARB . The fittings were performed through the use of ADAPT II 14 using the ordinary least squares estimator.
STATISTICAL ANALYSIS
Statistical analyses, including descriptive statistics as well as hypothesis testing, were performed using the SAS Release 8. 
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A P-value < 0.05 was considered statistically significant. Figure 1 shows the concentration-response relationships of rHuEPO and DARB in promoting BFU-E-derived colony formation from bone marrow samples of subjects 1, 2 and 3, using a conversion factor of 1 µg of DARB being equivalent to 200 IU rHuEPO. 16 The concentration-response relationships represent a typical sigmoidal shape, with minimum and maximum effective concentrations for both rHuEPO and DARB. The data presented in Fig. 1 demonstrate that rHuEPO is more potent than DARB in promoting BFU-E colony formation. While rHuEPO promoted erythroid burst formation at concentrations as low as 0.002 IU/ml, DARB was required at concentrations ≥ 0.2 IU/ml. The minimum effective concentration of DARB was about 100-fold higher than that of rHuEPO. The maximum effects of rHuEPO occurred at concentrations of approximately 2 IU/ml for subjects 1 and 2 and at a concentration of approximately 20 IU/ml for subject 3. The maximum effective dosage of DARB was not reached in this study, as the highest dosage tested did not reach the dotted line that represents the projected peak number of BFU-E-derived colonies.
Results
The estimated EC 50 and E max values of rHuEPO as compared with DARB for the five donor subjects are presented in Table 1 . These data show the individual variability of the EC 50 values, ranging from 0.014 to 0.72 for rHuEPO and from 1.075 to 8.41 for DARB. Despite the variability, it was consistently noted that for each subject tested, the EC 50 was lower for rHuEPO than for DARB, with an approximately 10-fold difference being observed. In at least two of the bone marrow samples, the peak colony number was higher for the rHuEPO-containing cultures. The concentrations of rHuEPO and DARB that were used were not high enough to allow an accurate determination of E max , but in at least two of the individuals (subjects 2 and 3), E max appeared to be higher for rHuEPO. Table 1 also shows that the mean (n = 5) of the estimated EC 50 for rHuEPO was significantly lower than the mean for DARB (P = 0.034, two-sample paired t-test). The equivalent test failed to establish that the mean E max for rHuEPO was significantly higher than the mean E max for DARB. Figure 2 illustrates the erythroid colony sizes when cultured in different concentrations of rHuEPO and DARB. Concentrations of rHuEPO of 0.25 IU/ml produced larger and healthier looking BFU-E-derived colonies than DARB at 2 IU/ml.
The dose-response relationships of rHuEPO compared with DARB for their ability to promote BFU-E-derived colony formation were further explored in a study where both rHuEPO and DARB were added to bone marrow samples obtained from subjects 4 and 5 (Fig. 3) . Consistent with the observations in subjects 1 -3, rHuEPO resulted in a higher number of erythroid bursts than DARB. It appeared that rHuEPO reached E max at dosages > 2 IU/ml, whereas DARB did not reach E max until dosages > 20 IU/ml. We conducted an experiment to evaluate the effect of combining the optimum concentration of DARB (20 IU/ml) with different concentrations of rHuEPO or DARB. The number of BFU-E-derived colonies in DARB-containing cultures peaked at around 10 -20 IU/ml. As illustrated in Fig. 3 , the number of colonies in cultures containing 20 IU/ml of DARB could be further enhanced by adding rHuEPO. A dose-related increase in colony formation was observed such that the total number of colonies almost reached the peak attained by the optimum concentration of rHuEPO regulatory roles in the early stages, although erythropoietin is the main factor during the latter stages of red cell production. Erythropoietin affects colony formation by both BFU-E and CFU-E and acts on these progenitors through surface receptors, which are highly specific for the erythropoietin molecule. rHuEPO is a recombinant human erythropoietin with a native amino acid sequence that is identical to endogenous erythropoietin. 17 An X-ray crystallography study of erythropoietin with its receptor (EPOR) demonstrates a lock-and-key type of high affinity interaction; maximum binding has only been observed with erythropoietin molecules that contain the native amino acid sequence. 18 Peptide mimetics bind to the EPOR with high affinity similar to that seen with the endogenous erythropoietin molecule, but the biological activity as demonstrated by target cell proliferation is about 10-fold less. 19 DARB is another molecular mimetic that has been derived from the native erythropoietin sequence, but it contains five amino acid differences obtained by site-directed mutagenesis. 6 DARB has two additional N-linked glycosylation sites, resulting in a longer half-life but a reduced binding to the EPOR. 6, 7 Based on the knowledge that other erythropoietin mimetics, which show similar binding to the EPOR as rHuEPO, demonstrate inferior biological activities when compared with endogenous erythropoietin, 19 it was necessary to ascertain the true biological activity of DARB as compared with rHuEPO. The availability of erythropoietin analogues has also made it possible to delineate more clearly the impact of receptor-ligand interactions on signal transduction pathways leading to functional activities. A recent report on mouse bone marrow cells indicated that the EC 50 of DARB was about 10 -14-fold higher than that observed for rHuEPO. 8 In this study we examined the effect of rHuEPO and DARB on human bone marrow cultured in vitro, and compared the intrinsic pharmacological potency of the two molecules. The culture method is well established in this setting and has been used extensively to study haematological growth factors and evaluate diseases of bone marrow origin. 19, 20 Bone marrow cells derived from patients with defective progenitors usually perform relatively poorly in standard cultures, suggesting that these in vitro cultures are predictive of clinical status. 11 As reported previously, erythropoietin at relatively low concentrations supports the growth of both BFU-E and CFU-E. 11 While other factors such as IL-3, GM-CSF, and stem cell factor can influence the number and size of the colonies, erythropoietin is the rate-limiting factor in all erythroid cultures, as control cultures without added erythropoietin show no evidence of any erythroid growth. 10 Consistent with the animal data, 8 the EC 50 of DARB in our study was, on average, 10-fold higher than that of rHuEPO. This is likely to be due to the four-to five-fold reduction in binding of DARB to the receptor, which translates to a more profound loss in biological activity. 8 In contrast to the animal data, 8 our studies demonstrated that the total number of BFU-Ederived colonies in rHuEPO-and DARBcontaining cultures may not be equivalent. In some samples, cultures containing DARB showed a 30 -50% lower number of bursts than in rHuEPO-containing cultures. When rHuEPO was added to DARB, there was an increase in burst formation even at relatively low concentrations of rHuEPO. A similar effect could not be achieved by adding DARB at higher concentrations. This observation was consistent with the view that a subset of progenitor cells may not respond to DARB. One hypothesis could be that early progenitors have lower receptor affinity and NM Jamal, W Krzyzanski, W Cheung et al.
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therefore require exposure to a hormone with a higher binding affinity. Alternatively, juxtaposition of the receptors in early progenitors might be different to that in the more mature progenitors. As a consequence, DARB, a larger and more highly charged molecule, might be less able to activate receptors on this early progenitor subset. It is also conceivable that the signal transduction pathway mediated by DARB might be different from that mediated by rHuEPO and that a certain subset of progenitor cells might fail to respond to an altered signal pathway.
The culture conditions used in this study have been optimized for testing bone marrow cultures in clinical settings for the evaluation of marrow quality before allogenic bone marrow transplant and for the evaluation of haematological diseases. Whether this is the optimal condition for comparing different synthetic analogues of growth factors has not been fully validated. Further insight might be gained from experiments in which subsets of BFU-E are evaluated with additional analogues of erythropoietin. 
Conflicts of interest
